We continue to hear from individuals who allegedly experienced life-threatening episodes of Pradaxa internal bleeding.
New York, NY (PRWEB) March 09, 2014
Pradaxa lawsuit (http://www.pradaxalawsuithelp.com/) plaintiffs who may have experienced dangerous episodes of internal bleeding may be one step closer to arguing their cases in court, with the first of four bellwether trials slated to begin in September, Bernstein Liebhard LLP reports.
According to a recent Case Management Order, the first Pradaxa lawsuit trial has been scheduled for September 15th, 2014 in the U.S. District Court, Southern District of Illinois, and the second is expected to follow on December 1. The third has been given a start date of February 17th, 2015, and the last will take place on March 23rd, the Order indicates.
All of these cases similarly allege episodes of internal bleeding and other side effects caused by a blood thinner that entered the market in 2010. A recent Case List update posted on the Court’s website shows at least 2,230 Pradaxa lawsuits now filed in the federal proceeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“The scheduling of these four Pradaxa lawsuit trials is of great interest to our Firm, as we continue to hear from individuals who allegedly experienced life-threatening episodes of internal bleeding after use of the blood thinner,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Pradaxa. The Firm is offering free and confidential case evaluations to individuals who may have been injured as a result of taking this medication.
All Pradaxa lawsuits now pending in the U.S. Southern District of Illinois accuse Boehringer-Ingelheim of failing to warn patients and their doctors about side effects associated with the drug, which may include cerebral hemorrhage, gastrointestinal bleeding, and other serious episodes of internal bleeding. Claimants further allege that the company failed to alert the general public that there is readily available antidote to stop episodes of Pradaxa bleeding once they begin, making them life-threatening. Since its entrance into the U.S. market, the blood thinner used to prevent strokes and heart attacks in patients with atrial fibrillation has been marketed as an alternative to the decades-old medication, warfarin. Internal bleeding episodes stemming from use of warfarin may be reversed with the administration of Vitamin K.
According to a recent media investigation led by 7 Action News in Detroit, Pradaxa may be the most complained about drug in America. A total of 12,494 injury reports were made to the U.S. Food and Drug Administration (FDA) between 2011 and 2012, along with 1,158 deaths. No other prescription drug on the market was associated with as many adverse events, the investigation found.*
Despite these injury and death reports, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication in November 2012 to announce that its assessment of Pradaxa bleeding rates vs. those associated with warfarin did not reveal an increased risk for those who took the Boehringer drug.
In December 2013, the FDA announced a new, large-scale assessment of Pradaxa bleeding rates in relation to warfarin.**
Individuals who may have experienced serious episodes of Pradaxa internal bleeding may be eligible to receive compensation for damages incurred by their alleged injuries. To learn more about Pradaxa bleeding side effects that may stem from use of the blood thinner, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange a free and confidential lawsuit evaluation.
*wxyz.com/money/consumer/pradaxa-lawsuit, 7 Action News, February 25, 2014
**mini-sentinel.org/assessments/medical_events/details.aspx?ID=219, FDA, December 30, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for
this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com